JACOBS-HOLDING-AG
17.4.2024 11:06:32 CEST | Business Wire | Press release
Jacobs Holding today announced that the board of directors has appointed Timothy Franks as Chief Executive Officer effective May 1, 2024.
With an impressive 25-year career at two prominent investment firms, Tim brings extensive experience and a proven track record in global private equity. His most recent role was as a Partner and Co-CEO of the democratized private equity business at KKR. He played a pivotal role in building KKR’s European franchise, leading the EMEA Core strategy, and overseeing the development of activities in the UK & Ireland, as well as the Consumer industry team in EMEA. Prior to that, Tim spent 17 years at Advent International, where he notably opened and led the New York office from 2010 to 2013. Throughout his tenure at both firms, he held various chair and board positions at portfolio companies.
Under his leadership, Jacobs Holding aims at further strengthening its investment activities, particularly in the services, healthcare and consumer industries. Tim’s strong investment focus on helping businesses with their sustainability and digitalization goals will be pivotal for Jacobs Holding in consolidating its investment approach, and investing in the growth potential of existing and future portfolio companies.
Nicolas and Philippe Jacobs, Co-Chairmen commented: “We are excited to have Tim join Jacobs Holding. Beyond being a highly accomplished private equity manager with an impressive track record, he has proven himself as a strong leader. Tim possesses all the qualities needed to get Jacobs Holding to the next level as a sustainable and entrepreneurial investor.”
Timothy Franks commented: “I look forward to working with the Jacobs team. It will be a real privilege to lead Jacobs Holding, given the strong purpose of the firm and its investment approach, which intersects three investment trends in alternative asset management: focusing on direct investments, pursuing a long-term investment horizon, and bringing sustainability and digitalization to the core of its activities.”
About Jacobs Holding AG
Jacobs Holding is a global professional investment firm founded by late entrepreneur Klaus J. Jacobs, in which he bundled his entrepreneurial activities in 1994. Jacobs Holding invests with a long-term horizon in companies active in non-cyclical businesses which already have or aim for a leading market position and have further growth and value creation potential. The current portfolio of Jacobs Holding consists of Cognita (www.cognita.com), Colosseum Dental Group (www.colosseumdental.com), North American Dental Group (www.nadentalgroup.com) as well as a large stake in the publicly traded company Barry Callebaut AG (www.barry-callebaut.com). The sole economic beneficiary of Jacobs Holding is the Jacobs Foundation, one of the world's leading charitable foundations for the promotion of development opportunities for children and young people. Since the foundation was established in 1989, around CHF 800 million has been paid out cumulatively.
Additional features:
File: JAG_CEO_English
File: Picture Timothy Franks
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417007318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release
Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our
Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release
H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE
Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan
Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release
Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
